Centiva Capital, LP Moderna, Inc. Call Options Transaction History

Centiva Capital, LP

$4.79 Billion
Q3 2024

Call Options

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$63.64 - $125.14 $197,284 - $387,934	-3,100 Reduced 44.29%	3,900 $260,000
Q2 2024 Aug 14, 2024	BUY	$101.21 - $166.61 $708,470 - $1.17 Million	7,000 New	7,000 $831,000
Q4 2023 Feb 14, 2024	SELL	$69.51 - $104.43 $597,786 - $898,098	-8,600 Reduced 74.14%	3,000 $298,000
Q3 2023 Nov 14, 2023	SELL	$96.41 - $126.61 $867,690 - $1.14 Million	-9,000 Reduced 43.69%	11,600 $1.2 Million
Q2 2023 Aug 14, 2023	SELL	$118.5 - $160.53 $3.45 Million - $4.67 Million	-29,100 Reduced 58.55%	20,600 $2.5 Million
Q1 2023 May 15, 2023	SELL	$135.66 - $197.02 $7.31 Million - $10.6 Million	-53,900 Reduced 52.03%	49,700 $7.63 Million
Q4 2022 Feb 14, 2023	BUY	$118.38 - $210.04 $3.49 Million - $6.2 Million	29,500 Added 39.81%	103,600 $18.6 Million
Q3 2022 Nov 14, 2022	SELL	$118.07 - $194.18 $4.9 Million - $8.06 Million	-41,500 Reduced 35.9%	74,100 $8.76 Million
Q2 2022 Aug 17, 2022	BUY	$117.13 - $176.59 $8.2 Million - $12.4 Million	70,000 Added 153.51%	115,600 $16.5 Million
Q1 2022 May 16, 2022	SELL	$126.46 - $235.05 $6.16 Million - $11.4 Million	-48,700 Reduced 51.64%	45,600 $7.85 Million
Q4 2021 Feb 14, 2022	BUY	$225.82 - $368.51 $20 Million - $32.6 Million	88,360 Added 1487.54%	94,300 $24 Million
Q3 2021 Nov 15, 2021	SELL	$221.9 - $484.47 $12.6 Million - $27.6 Million	-56,960 Reduced 90.56%	5,940 $2.28 Million
Q2 2021 Aug 16, 2021	BUY	$129.91 - $234.98 $3.98 Million - $7.19 Million	30,600 Added 94.74%	62,900 $14.8 Million
Q1 2021 May 17, 2021	BUY	$109.18 - $185.98 $3.53 Million - $6.01 Million	32,300 New	32,300 $4.23 Million

Others Institutions Holding MRNA

# of Institutions

938

Shares Held

240M

Call Options Held

10.6M

Put Options Held

18.7M

View Full List

About Moderna, Inc.

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $14B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

More about MRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.

Account